Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

Launched by ANN-SOFIE BACKMAN · Jun 3, 2021

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called mesalamine can help prevent colorectal cancer in people with Lynch Syndrome, a genetic condition that increases the risk of certain cancers. The trial will involve about 200 participants who will take either mesalamine or a placebo (a dummy treatment) every day for two years. Researchers want to see if mesalamine can lower the chances of developing colorectal tumors in these patients.

To be eligible for this study, participants must be at least 30 years old and have a specific genetic mutation related to Lynch Syndrome, but they must not have any existing colorectal tumors that cannot be removed. Women who can become pregnant must use effective birth control during the study. Participants will need to provide consent and will be closely monitored throughout the trial to ensure their safety. This is an important step in understanding how to better prevent cancer in individuals with Lynch Syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Proven tumor-free (including patients in which the polyps are removed endoscopically) carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
• • Male or female subjects with the age of 30 years or older
• • Females who have been post-menopausal more than one (1) year or females of childbearing potential using a highly efficient method of contraception with less than 1% failure rate (i.e. oral hormonal contraceptives, hormone implants, hormone injections, sterilization, hormonal or copper intrauterine device, sterilized/vasectomized partner, or diaphragm in combination with a condom, spermicide or birth control pills) or should agree to abstain from heterosexual activity during treatment period. Females of childbearing potential must have a negative pregnancy test at screening and before randomization.
• • Signed written informed consent prior to inclusion in the study
• Exclusion Criteria:
• • Presence of colorectal endoscopically non-removable benign neoplasia (patient can be included if the adenoma is removed)
• • Carriers of germline mutations in PMS2
• • Patients with history of stage 3 and 4 CRC are excluded
• • Presence of metastatic disease
• • Regular use of aspirin/ASA: daily use of ≥100mg in more than 3 continuous months within the last year
• • Regular use of NSAIDs or COX-2 inhibitors: daily use in more than 3 continuous months within the last year
• • Hypersensitivity to 5-ASA
• • Patients after any subtotal or total colectomy
• • Colorectal surgery within the previous 6 months
• • Unwillingness to participate or who is considered incompetent to give an informed consent
• • Pregnant or breastfeeding women
• • Participation in another clinical study investigating another IMP within 1 month prior to screening
• • Renal insufficiency (GFR \<30ml/min/1.73m2)
• • Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
• • Current or history of serious psychiatric disorder or alcohol/drug abuse that in the opinion of the investigator may impact the assessment of IMP safety and efficacy or protocol adherence
• • Prior history of myocarditis or pericarditis. Other severe acute or chronic medical condition such as severe chronic lung (COPD, including asthma, kidney and heart diseases) or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, investigational product administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study